CHALFONT ST. GILES, UK -- 22 January 2014 -- GE Healthcare (NYSE:GE), today announced that biopharmaceutical company Nanotherapeutics, Inc. has selected GE Healthcare Life Sciences' FlexFactory™ biomanufacturing platform to perform a central role in its Advanced Development and Manufacturing (NANO-ADM) Center at Alachua, Florida, USA. Construction of the NANO-ADM Center, which began in October 2013, is expected to be complete in early 2015.
business unit
tags
GE to expand in fast-growing Life Sciences sectors; extends bioprocessing manufacturing footprint in Asia, the Americas and Europe
GE to acquire cell culture media and sera, gene modulation and magnetic beads businesses
Supports the development of technologies for research and manufacture of innovative new medicines
business unit
tags
Analysis of Multiplexed Proteins at Single-Cell Level Provides a Deeper Understanding of Cancer
ALISO VIEJO, CA, December 9, 2013 -- GE Healthcare today announced results from two studies that show how using the MultiOmyx™ Hodgkin Lymphoma (HL) Profile and an investigational profile for breast cancer may improve assessment of the two diseases in subsets of patients.
business unit
tags
CARDIFF, UK -- 4 December 2013 -- Dr. Nina Moran from GE Healthcare Life Sciences will be swapping a lab coat for legislation, when she visits Mr. Roger Williams MP for Brecon and Radnorshire, at the House of Commons for a "Week in Westminster" as part of a unique 'pairing' scheme run by the Royal Society -- the UK's national academy of science.
business unit
tags
Chalfont St Giles, UK and Hsinchu, Taiwan -- 2 December 2013 -- GE Healthcare Life Sciences, (NYSE: GE), and JHL Biotech today announced that GE Healthcare has completed installation of its FlexFactory™ biomanufacturing platform at JHL Biotech's Research Center and manufacturing plant in Hsinchu, Taiwan. The new manufacturing platform will follow current good manufacturing practices (cGMP) and be fully operational by the end of 2013.
business unit
tags
Princeton, NJ -- November 27, 2013 -- GE Healthcare today announced results from a new study, which showed that patients receiving Visipaque™ (iodixanol 320mg I/ml) were less likely to experience discomfort, characterized by heat or cold sensation or pain upon injection, than patients receiving Isovue® (iopamidol 370 mg I/ml). As with other iodinated contrast agents, Visipaque is often associated with sensations of discomfort, heat or pain. The data were published online in Acta Radiologica.[i]
business unit
tags
CHALFONT ST. GILES, UK -- 19 November 2013 -- GE Healthcare Life Sciences, (NYSE: GE) and Cellectis Group (Alternext: ALCLS), the global genome engineering specialist, announced today that GE Healthcare has licenced Cellectis to develop, manufacture and sell models derived from stem cells for use in drug discovery and toxicity screening.